[go: up one dir, main page]

WO2009017838A3 - Combinations of jak-2 inhibitors and other agents - Google Patents

Combinations of jak-2 inhibitors and other agents Download PDF

Info

Publication number
WO2009017838A3
WO2009017838A3 PCT/US2008/009360 US2008009360W WO2009017838A3 WO 2009017838 A3 WO2009017838 A3 WO 2009017838A3 US 2008009360 W US2008009360 W US 2008009360W WO 2009017838 A3 WO2009017838 A3 WO 2009017838A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitor
jak
mammal
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/009360
Other languages
French (fr)
Other versions
WO2009017838A2 (en
Inventor
Peter Lamb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of WO2009017838A2 publication Critical patent/WO2009017838A2/en
Publication of WO2009017838A3 publication Critical patent/WO2009017838A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J) as described in the specification, or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J) and a pharmaceutically acceptable carrier, in combination with an active agent selected from of a Raf inhibitor, an EGFR inhibitor, a VEGFR inhibitor, a ErbB2 inhibitor, a BCR-Abl, inhibitor, a Flt3 inhibitor, a Src inhibitor, a c Kit inhibitor, an Akt inhibitor, a Ret inhibitor, an IFG1R inhibitor, an m-Tor inhibitor, a PI3K inhibitior, a PI3Kalpha inhibitor, wherein the mammal is in need of the treatment.
PCT/US2008/009360 2007-08-01 2008-07-31 Combinations of jak-2 inhibitors and other agents Ceased WO2009017838A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96277607P 2007-08-01 2007-08-01
US60/962,776 2007-08-01

Publications (2)

Publication Number Publication Date
WO2009017838A2 WO2009017838A2 (en) 2009-02-05
WO2009017838A3 true WO2009017838A3 (en) 2009-07-02

Family

ID=39847031

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/009360 Ceased WO2009017838A2 (en) 2007-08-01 2008-07-31 Combinations of jak-2 inhibitors and other agents

Country Status (1)

Country Link
WO (1) WO2009017838A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106536503A (en) * 2014-04-18 2017-03-22 山东轩竹医药科技有限公司 Tyrosine kinase inhibitor and uses thereof

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009032668A2 (en) 2007-08-28 2009-03-12 Irm Llc 2 -biphenylamino-4 -aminopyrimidine derivatives as kinase inhibitors
CA2698511C (en) * 2007-09-04 2016-10-11 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
UY31800A (en) * 2008-05-05 2009-11-10 Smithkline Beckman Corp CANCER TREATMENT METHOD USING A CMET AND AXL INHIBITOR AND AN ERBB INHIBITOR
US8445505B2 (en) 2008-06-25 2013-05-21 Irm Llc Pyrimidine derivatives as kinase inhibitors
PE20100087A1 (en) 2008-06-25 2010-02-08 Irm Llc COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS
CN102203083A (en) * 2008-06-25 2011-09-28 Irm责任有限公司 Compounds and compositions as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) * 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
DK2361248T3 (en) 2008-06-27 2019-01-14 Celgene Car Llc Heteroberl compounds and uses thereof
PT3372605T (en) 2008-10-22 2021-12-09 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
US8759362B2 (en) * 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
HRP20140265T1 (en) * 2009-02-06 2014-04-25 Nippon Shinyaku Co., Ltd. Aminopyrazine derivative and drug
MX2011009926A (en) * 2009-03-21 2012-01-27 Ning Xi Amino ester derivatives, salts thereof and methods of use.
EP2440559B1 (en) 2009-05-05 2018-01-10 Dana-Farber Cancer Institute, Inc. Egfr inhibitors and methods of treating disorders
AR077033A1 (en) * 2009-06-11 2011-07-27 Hoffmann La Roche INHIBITING COMPOUNDS OF JANUS KINASES AND THEIR USE IN THE TREATMENT OF IMMUNOLOGICAL DISEASES
AR077468A1 (en) 2009-07-09 2011-08-31 Array Biopharma Inc PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
WO2011018517A1 (en) 2009-08-14 2011-02-17 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
JP5792171B2 (en) * 2009-09-04 2015-10-07 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Compositions and methods for treating leukemia
EP2311809A1 (en) * 2009-10-16 2011-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Quinolinyloxyphenylsulfonamides
RU2528386C2 (en) 2010-05-21 2014-09-20 Кемилиа Аб New pyrimidine derivatives
BR122014012788B1 (en) 2010-06-23 2022-04-19 Hanmi Science Co., Ltd Fused pyrimidine derivatives, their uses, and pharmaceutical composition for inhibiting tyrosine kinase activity
US9586961B2 (en) 2010-07-09 2017-03-07 Leo Pharma A/S Homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
KR20130099040A (en) 2010-08-10 2013-09-05 셀진 아빌로믹스 리서치, 인코포레이티드 Besylate salt of a btk inhibitor
JPWO2012020786A1 (en) * 2010-08-11 2013-10-28 日本新薬株式会社 Pharmaceutical composition
WO2012020787A1 (en) * 2010-08-11 2012-02-16 日本新薬株式会社 Malignant lymphoma therapeutic agent
JP5957460B2 (en) 2010-11-01 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド Heterocyclic compounds or uses thereof
EP2635285B1 (en) 2010-11-01 2017-05-03 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
JP5957003B2 (en) 2010-11-10 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド Mutant selective EGFR inhibitor and use thereof
WO2012065019A2 (en) * 2010-11-12 2012-05-18 Exelixis, Inc. Pyridopyrimidinone inhibitors of p13k alpha
WO2012065057A2 (en) * 2010-11-12 2012-05-18 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use
BR112013012078A2 (en) 2010-11-15 2019-09-24 Abbvie Inc nampt and rock inhibitors
CA2830129C (en) 2011-03-24 2016-07-19 Chemilia Ab Novel pyrimidine derivatives
AR086744A1 (en) * 2011-06-28 2014-01-22 Nippon Soda Co HETEROCICLIC COMPOUND CONTAINING NITROGEN AND FUNGICIDE FOR USE IN AGRICULTURE AND GARDENING
CN102408411B (en) * 2011-09-19 2014-10-22 北京康辰药业股份有限公司 Hydroximic acid compound containing quinolyl and preparation method thereof, and drug composition containing the compound and use thereof
AR088570A1 (en) 2011-10-28 2014-06-18 Celgene Avilomics Res Inc METHODS TO TREAT AN ILLNESS OR DISORDER RELATED TO BRUTON TYROSINE KINASE
SG10201603411WA (en) * 2011-10-28 2016-07-28 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
WO2013067141A1 (en) * 2011-11-01 2013-05-10 Exelixis, Inc. N- (3- { [ (3- { [2-chloro-5- (methoxy) phenyl] amino} quinoxalin- 2 -yl) amino] sulfonyl} phe nyl) - 2 -methylalaninamide as phosphatidylinositol 3 - kinase inhibitor for the treatment of lymphoproliferative malignancies
US9586965B2 (en) 2012-01-13 2017-03-07 Acea Biosciences Inc. Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
US10799504B2 (en) 2012-01-13 2020-10-13 ACEA Therapeutics, Inc. Heterocyclic compounds and uses as anticancer agents
US9464089B2 (en) 2012-01-13 2016-10-11 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
DK2825042T3 (en) 2012-03-15 2018-11-26 Celgene Car Llc SALTS OF THE CHINASE INHIBITOR OF THE EPIDERMAL GROWTH FACTOR RECEPTOR
US9056839B2 (en) 2012-03-15 2015-06-16 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
CN103804307A (en) * 2012-11-06 2014-05-21 韩冰 Compound for treatment of ischemic brain damage and application thereof
WO2014076484A1 (en) 2012-11-16 2014-05-22 Respivert Limited Kinase inhibitors
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
MX2015009952A (en) 2013-02-08 2015-10-05 Celgene Avilomics Res Inc Erk inhibitors and uses thereof.
CA2900680C (en) * 2013-02-20 2021-08-10 Kala Pharmaceuticals, Inc. Quinoline and quinazoline compounds and uses thereof for treating and/or preventing diseases
CN104072499A (en) * 2013-03-29 2014-10-01 黄传满 Piperazine substituted pyrimidine compounds and applications thereof
ES2761572T3 (en) 2013-07-11 2020-05-20 Acea Therapeutics Inc Pyrimidine derivatives as kinase inhibitors
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
CN104860941B (en) * 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4-disubstituted phenyl-1,5-diamine derivatives and use thereof, and pharmaceutical composition and medicinal composition prepared from 2,4-disubstituted phenyl-1,5-diamine derivative
EP3179858B1 (en) 2014-08-13 2019-05-15 Celgene Car Llc Forms and compositions of an erk inhibitor
US10246464B2 (en) 2014-09-09 2019-04-02 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
CA2967951C (en) 2014-11-16 2023-11-07 Array Biopharma, Inc. Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
CN104817553B (en) * 2015-03-13 2018-11-09 华东师范大学 The pyrimidinediamine class compound and its derivative and its medical usage of a kind of aromatic radical-heterocyclic substituted
WO2016169417A1 (en) * 2015-04-21 2016-10-27 成都金瑞长青生物科技有限公司 Purinyl-n-hydroxyl pyrimidine formamide derivatives, preparation method therefor and use thereof
AR104020A1 (en) 2015-06-04 2017-06-21 Kura Oncology Inc METHODS AND COMPOSITIONS TO INHIBIT THE INTERACTION OF MENINA WITH MILL PROTEINS
WO2016197027A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
SI3322706T1 (en) 2015-07-16 2021-04-30 Array Biopharma, Inc. Substituted pyrazolo(1,5-a)pyridine compounds as ret kinase inhibitors
JP6889494B2 (en) 2015-10-09 2021-06-18 エイシア セラピューティクス， インコーポレイテッド Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making them.
SG10201912959QA (en) 2015-10-21 2020-02-27 Otsuka Pharma Co Ltd Benzolactam compounds as protein kinase inhibitors
CA3003153A1 (en) 2015-10-26 2017-05-04 Loxo Oncology, Inc. Point mutations in trk inhibitor-resistant cancer and methods relating to the same
CN106810536A (en) 2015-11-30 2017-06-09 甘李药业股份有限公司 A kind of kinases inhibitor and preparation method thereof and medical usage
CN105541798B (en) * 2016-02-03 2018-01-23 中国人民解放军第二军医大学 Quinolines Mutiple Targets kinase inhibitor with antitumor activity and preparation method thereof
SMT202300273T1 (en) 2016-03-16 2023-09-06 Kura Oncology Inc Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use
MX387806B (en) 2016-03-16 2025-03-19 Kura Oncology Inc Bridged bicyclic inhibitors of menin-mll and methods of use
PH12018502124B1 (en) 2016-04-04 2024-04-12 Loxo Oncology Inc Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
JP7057343B2 (en) 2016-04-04 2022-04-19 ロクソ オンコロジー， インコーポレイテッド How to treat childhood cancer
PT3458456T (en) 2016-05-18 2020-12-07 Array Biopharma Inc Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-y l)-3-hydroxypyrrolidine-1-carboxamide
WO2017210545A1 (en) 2016-06-02 2017-12-07 Cadent Therapeutics, Inc. Potassium channel modulators
JOP20190077A1 (en) 2016-10-10 2019-04-09 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TWI704148B (en) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
JOP20190092A1 (en) 2016-10-26 2019-04-25 Array Biopharma Inc PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
US11046683B2 (en) 2016-12-15 2021-06-29 Ono Pharmaceutical Co., Ltd. Activator of TREK (TWIK RElated K+ channels) channels
CA3049136C (en) 2017-01-18 2022-06-14 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
LT3571193T (en) 2017-01-23 2022-02-10 Cadent Therapeutics, Inc. Potassium channel modulators
JOP20190213A1 (en) 2017-03-16 2019-09-16 Array Biopharma Inc Macrocyclic compounds as ros1 kinase inhibitors
WO2018175746A1 (en) 2017-03-24 2018-09-27 Kura Oncology, Inc. Methods for treating hematological malignancies and ewing's sarcoma
BR112019020840A2 (en) 2017-04-07 2020-04-28 Acea Therapeutics Inc pharmaceutical salts, physical forms and compositions of pyrrolopyrimidine kinase inhibitors and methods of producing them
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
CN108794480A (en) * 2017-04-28 2018-11-13 天津药物研究院有限公司 Azolopyrimidines, preparation method and use
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
TW201920170A (en) 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 Substituted MENIN-MLL inhibitor and method of use
TWI876442B (en) 2017-10-10 2025-03-11 美商絡速藥業公司 Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
TWI791053B (en) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof
JP6997876B2 (en) 2018-01-18 2022-02-04 アレイ バイオファーマ インコーポレイテッド Substituted pyrazolyl [4,3-C] pyridine compound as a RET kinase inhibitor
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
US11524963B2 (en) 2018-01-18 2022-12-13 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors
WO2019148043A1 (en) * 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
CN108707145B (en) * 2018-07-05 2021-02-26 沈阳药科大学 Quinoline compounds containing five-membered heterocyclic structure and their preparation and application
ES2922314T3 (en) 2018-09-10 2022-09-13 Array Biopharma Inc Fused Heterocyclic Compounds as RET Kinase Inhibitors
KR20210080446A (en) 2018-10-22 2021-06-30 카덴트 테라퓨틱스, 인크. Crystalline Forms of Potassium Channel Modulators
TWI740288B (en) * 2018-11-27 2021-09-21 大陸商江蘇豪森藥業集團有限公司 Nitrogen-containing heteroaromatic derivative regulator, preparation method and application thereof
WO2020118683A1 (en) * 2018-12-14 2020-06-18 Lynk Pharmaceuticals Co. Ltd. Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
WO2020160151A1 (en) 2019-01-31 2020-08-06 Kyorin Pharmaceutical Co., Ltd. 15-pgdh inhibitors
WO2021062163A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
CN113583020B (en) * 2020-04-30 2022-04-22 百极弘烨（广东）医药科技有限公司 JAK2 inhibitor and application
WO2021231798A1 (en) 2020-05-13 2021-11-18 Disc Medicine, Inc. Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
CN112225729B (en) * 2020-11-04 2022-02-01 四川大学华西医院 Pyrimidine derivative, preparation method and application thereof and pharmaceutical composition
CN113045479B (en) * 2021-03-29 2022-05-24 南京工业大学 A kind of synthetic method of visible light-promoted 3-hydroxyisoindol-1-one compounds
CN113735859A (en) * 2021-08-12 2021-12-03 安徽医科大学 Kinase inhibitor
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
EP4455139A4 (en) * 2021-12-21 2025-09-24 Wigen Biomedicine Tech Shanghai Co Ltd COMPOUND AS A FAK INHIBITOR AND USE THEREOF
WO2023229685A2 (en) * 2022-02-24 2023-11-30 Microbiotix, Inc. Broad-spectrum inhibitors of cytomegalovirus
CN114751927B (en) * 2022-03-08 2023-10-31 中山大学 Boric acid compound, preparation method and application
IL316556A (en) * 2022-04-29 2024-12-01 Beigene Ltd Substituted 6- (pyrimidin-4-yl) quinoline compounds as cyclin dependent kinase inhibitors
CN120077038A (en) * 2022-10-27 2025-05-30 百济神州(苏州)生物科技有限公司 Substituted 6- (pyrimidin-4-yl) quinoline compounds as cyclin dependent kinase inhibitors
CN116496234B (en) * 2023-02-09 2024-09-13 江苏润安制药有限公司 Preparation method of urapidil hydrochloride key intermediate
CN116903592B (en) * 2023-07-13 2025-08-01 特科罗生物科技(成都)有限公司 Pyrimidamine NUAK inhibitor and preparation method and application thereof
CN117088851A (en) * 2023-07-13 2023-11-21 特科罗生物科技(成都)有限公司 A pyrimidine amine NUAK inhibitor and its preparation method and use
CN118994031A (en) * 2024-07-31 2024-11-22 吉林大学 Novel pyrimidine biphenyl derivative with anti-tumor activity and preparation method and application thereof

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997019065A1 (en) * 1995-11-20 1997-05-29 Celltech Therapeutics Limited Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
WO2004041789A1 (en) * 2002-11-01 2004-05-21 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of jak and other protein kinases
WO2005012262A1 (en) * 2003-07-30 2005-02-10 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
WO2005112932A2 (en) * 2004-05-07 2005-12-01 Exelixis, Inc. Raf modulators and methods of use
WO2007023186A1 (en) * 2005-08-26 2007-03-01 Laboratoires Serono S.A. Pyrazine derivatives and use as pi3k inhibitors
WO2007044698A1 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
WO2007044729A2 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
WO2007053573A2 (en) * 2005-10-31 2007-05-10 Bayer Pharmaceuticals Corporation Treatment of cancer with sorafenib
WO2007059155A1 (en) * 2005-11-14 2007-05-24 Bayer Pharmaceuticals Corporation Treatment of cancers having resistance to chemotherapeutic agents
US20070149484A1 (en) * 2005-11-11 2007-06-28 Zentaris Gmbh Novel pyridopyrazines and their use as modulators of kinases
WO2007084786A1 (en) * 2006-01-20 2007-07-26 Novartis Ag Pyrimidine derivatives used as pi-3 kinase inhibitors
WO2007089768A2 (en) * 2006-01-30 2007-08-09 Exelixis, Inc. 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them
WO2008021389A2 (en) * 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997019065A1 (en) * 1995-11-20 1997-05-29 Celltech Therapeutics Limited Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
WO2004041789A1 (en) * 2002-11-01 2004-05-21 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of jak and other protein kinases
WO2005012262A1 (en) * 2003-07-30 2005-02-10 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
WO2005112932A2 (en) * 2004-05-07 2005-12-01 Exelixis, Inc. Raf modulators and methods of use
WO2007023186A1 (en) * 2005-08-26 2007-03-01 Laboratoires Serono S.A. Pyrazine derivatives and use as pi3k inhibitors
WO2007044729A2 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
WO2007044698A1 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
WO2007053573A2 (en) * 2005-10-31 2007-05-10 Bayer Pharmaceuticals Corporation Treatment of cancer with sorafenib
US20070149484A1 (en) * 2005-11-11 2007-06-28 Zentaris Gmbh Novel pyridopyrazines and their use as modulators of kinases
WO2007059155A1 (en) * 2005-11-14 2007-05-24 Bayer Pharmaceuticals Corporation Treatment of cancers having resistance to chemotherapeutic agents
WO2007084786A1 (en) * 2006-01-20 2007-07-26 Novartis Ag Pyrimidine derivatives used as pi-3 kinase inhibitors
WO2007089768A2 (en) * 2006-01-30 2007-08-09 Exelixis, Inc. 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them
WO2008021389A2 (en) * 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TURNER B ET AL: "American Chemical Society - 233rd national meeting. Novel drugs for the treatment of cancer", IDRUGS 200705 GB, vol. 10, no. 5, May 2007 (2007-05-01), pages 300 - 301, XP002526684, ISSN: 1369-7056 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106536503A (en) * 2014-04-18 2017-03-22 山东轩竹医药科技有限公司 Tyrosine kinase inhibitor and uses thereof
US10300058B2 (en) 2014-04-18 2019-05-28 Xuanzhu Pharma Co., Ltd. Tyrosine kinase inhibitor and uses thereof
CN106536503B (en) * 2014-04-18 2019-09-06 北京澳合药物研究院有限公司 A kind of tyrosine kinase inhibitor and its use

Also Published As

Publication number Publication date
WO2009017838A2 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
WO2009017838A3 (en) Combinations of jak-2 inhibitors and other agents
WO2008124085A3 (en) Methods of using combinations of mek and jak-2 inhibitors
WO2009128918A8 (en) Combination therapy using a soluble hyaluronidase and a bisphosphonate
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
MY148688A (en) 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
EP2512479A4 (en) Methods and compositions for treating peripheral vascular disease
WO2008054454A3 (en) Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
EA200970932A1 (en) METHODS OF TREATMENT WITH THE APPLICATION OF PYRIDOPYRIMIDINONOVES INHIBITORS PI3K ALPHA
FI2694072T4 (en) Combination of akt inhibitor compound and abiraterone for use in therapeutic treatments
JO3147B1 (en) Substituted 2,3-dihydroimidazo[ 1,2- c] quinazoline Derivatives Useful for Treating Hyper-Proliferative Disorders And Diseases Associated with Angiogenesis
CO6761350A2 (en) Derivatives of 2,3-dihydroimidazo [1,2-c] quinazoline substituted with amino alcohols that are useful for treating hyperproliferative disorders and diseases associated with angiogenesis
WO2010048087A3 (en) Compositions and methods for treating periodontal disease comprising clonidine, sulindac and/or fluocinolone
IL194883A0 (en) Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and paracetamol
MX2010004252A (en) Organic compounds.
WO2007095615A3 (en) Use of benzo-heteroaryl sulfamide derivatives for the treatmentof pain
WO2006113498A3 (en) 2-amino-quinaz0lin-5-ones as hsp90 inhibitors useful in treating proliferation diseases
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
UA96304C2 (en) 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
RU2008148597A (en) PHARMACEUTICAL COMBINATIONS
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors
WO2006083780A3 (en) Glucuronidated nebivolol
TNSN08506A1 (en) Substituted carboxamides
WO2009019708A3 (en) Pharmaceutical compositions and methods for the treatment of cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2008795008

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08795008

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE